CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patients.
BACKGROUND
Rituximab (RTX) is a B cell-depleting agent approved for the treatment of granulomatosis with polyangiitis (GPA). RTX reduces antibody producing precursor plasma cells and inhibits B and T cells interaction. Infections related to T cell immunodeficiency are not infrequent during RTX treatment. Our study investigated CD4 cell count and CD4/CD8 ratio in GPA patients during the first two years of long-term RTX treatment.


METHODS
A single centre cohort study of 35 patients who received median total cumulative dose of cyclophosphamide (CYC) of 15 g and were treated with RTX 2 g followed by retreatment with either 2 g once annually or 1 g biannually. Serum levels of total immunoglobulin (Ig) and lymphocytes subsets were recorded at RTX initiation and at 3, 6, 12, 18 and 24 months. Low CD4 count and inverted CD4/CD8 ratio were defined as CD4 < 0.3 × 10(9)/l and ratio < 1.


RESULTS
The CD4 cell count and CD4/CD8 ratio decreased slightly following the initial RTX treatment and then increased gradually during maintenance treatment. While the proportion of patients with low CD4 cell count decreased from 43% at baseline to 18% at 24 months, the ratio remained inverted in 40%. Oral daily prednisolone dose at baseline, CYC exposure and the maintenance regimen did not influence the CD4 cell count and ratio. Being older (p = 0.012) and having a higher CRP (p = 0.044) and ESR (p = 0.024) at baseline significantly increased the risk of inverted CD4/CD8 ratio at 24 months. Inverted ratio at baseline associated with lower total Ig levels during the study.


CONCLUSIONS
Overall, the CD4 and CD4/CD8 ratio increased during maintenance RTX therapy in GPA with no discernible impact of other immunosuppressive therapy. However the increase in CD4 was not followed by an increase in the CD4/CD8 ratio, especially in older patients. Inverted CD4/CD8 ratio associated with lower Ig levels, suggesting a more profound B cell depleting effect of RTX with a relative increase in CD8+ lymphocytes.
Bone and Joint Research Group, Institute of Clinical Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway , Tromsø , Norway.
Emilio
0000-0002-7006-9201
E
Besada
School of Medicine & Pharmacology QEII Medical Centre Unit, University of Western Australia, Australia; Rheumatology, Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
Johannes C
JC
Nossent
ANCA-associated vasculitis; B cell depletion; CD4 cell; CD4/CD8 ratio; CD8 cell; Granulomatosis with polyangiitis; Hypogammaglobulinemia; Immunosuppression; Infection; Rituximab
Br J Clin Pharmacol. 2008 Aug;66(2):320-2
18485050
Clin Exp Immunol. 2009 Aug;157(2):191-7
19604258
N Engl J Med. 2014 Nov 6;371(19):1771-80
25372085
Ann Rheum Dis. 2011 Mar;70 Suppl 1:i59-63
21339221
Arthritis Rheum. 2012 Nov;64(11):3770-8
22730028
Arthritis Res Ther. 2010;12(1):204
20236453
Arthritis Rheum. 2005 Feb;52(2):501-13
15693003
Ann Rheum Dis. 2008 Jul;67(7):917-25
17965121
QJM. 2012 Jun;105(6):545-50
22301823
Arthritis Rheum. 2012 Nov;64(11):3760-9
22729997
Rheumatology (Oxford). 2008 May;47(5):609-16
18346977
N Engl J Med. 2010 Jul 15;363(3):211-20
20647198
Kidney Int. 2006 Sep;70(5):938-47
16837919
N Engl J Med. 2010 Jul 15;363(3):221-32
20647199
Nat Rev Immunol. 2006 May;6(5):394-403
16622478
Rheumatology (Oxford). 2013 Nov;52(11):2041-7
23934313
Nephrol Dial Transplant. 2006 Jul;21(7):1825-32
16567340
Leuk Lymphoma. 2009 Jul;50(7):1083-95
19399690
Arthritis Rheum. 2013 Nov;65(11):2783-90
23918413
Arthritis Rheum. 2009 Jun;60(6):1578-87
19479864
Curr Opin Immunol. 2011 Aug;23(4):537-42
21652194
PLoS One. 2014 Nov 13;9(11):e112658
25393622
Curr Opin Rheumatol. 2014 Jan;26(1):1-6
24276087
Rheumatology (Oxford). 2014 Oct;53(10):1818-24
24831059
Arthritis Rheum. 2010 Sep;62(9):2625-32
20506353
Open Rheumatol J. 2008;2:81-8
19156222
J Clin Lab Immunol. 1992;38(3):103-9
1285384
QJM. 2014 Oct;107(10):821-8
24778295